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Enzymatic elimination of surface glycosaminoglycans or inhibition of their sulfation provokes sensitizing ofHT-29 andHeLa cells
toward the peptide bacteriocins nisinA, plantaricinC, and pediocin PA-1/AcH. The effect can be partially reversed by heparin, which
also lowers the susceptibility of Lactococcus lactis to nisin A. These data indicate that the negative charge of the glycosaminoglycan
sulfate residues binds the positively charged bacteriocins, thus protecting eukaryotic cells from plasmamembrane damage.
Bacteriocins are antimicrobial proteins produced by bacteria(1). Special attention has been devoted to peptides of between
20 and 40 amino acids produced by lactic acid bacteria (LAB)
because they are usually resistant to boiling and extreme pH levels,
which facilitates their use as preservatives in fermented foods (2).
These peptides are divided into two major groups; class I is com-
posed of molecules containing posttranslationally dehydrated ser-
ine and threonine residues and thioether linkages of these with
neighboring cysteines to form lanthionine and 3-methyl-lanthio-
nine, respectively, which is why they are termed “lantibiotics” (3,
4). Class II bacteriocins are composed of unmodified amino acids
(2). These two classes are further subdivided depending on their
secondary structure, the number of peptides that form the anti-
microbial, and the spectrum of susceptible bacteria. These bacte-
ricidal peptides usually insert into the plasma membrane, polym-
erize there, and produce a pore, thus abolishing the membrane
potential and inducing cytoplasmic solute leakage (5). These ef-
fects may be preceded by the recognition of membrane compo-
nents, such as lipids I to IV, which results in the interruption of cell
wall formation as well (4, 6, 7).
LAB bacteriocins are consumed with fermented foods because
the microbial starters produce them in the food matrix. Based on
this, nisin A and pediocin PA-1/AcH have been authorized for use
as food preservatives (8). Moreover, LAB are part of the autoch-
thonous microbiota and are believed to produce bacteriocins in
situ. However, there have been no reports on human or animal
toxicity attributable to bacteriocins, in spite of the fact that the
plasma membrane is an essential part of the eukaryotic cell. The
lack of toxicity of LAB bacteriocins might be due to their suscep-
tibility to digestive proteinases or to adsorption to food compo-
nents. However, nisin has been intraperitoneally injected to com-
bat experimental infections in mice with no secondary effects (9,
10). This suggests that peptide bacteriocins are unable to open
pores in the eukaryotic cell membrane. Alternatively, they might
not be able to reach the membrane because the eukaryotic glyco-
calyx may act as a barrier, as do the lipopolysaccharides of Gram-
negative bacteria (11).
Proteoglycans are part of the eukaryotic glycocalyx. They are
composed of a protein stem and sulfated polysaccharide branches,
called glycosaminoglycans (GAGs), that give a net negative charge
to the polymer (12) and might help in blocking bacteriocins, most
of which are positively charged.
Testing of this hypothesis was done by eliminating the GAG
layer from the surface of cell cultures and questioning whether it
made the component cells susceptible to representative peptide
bacteriocins. We used nisin A (a linear lantibiotic that needs an
energized bacterial plasma membrane for efficient activity) (13),
plantaricin C (a globular lantibiotic that does not need a potential
across the membrane) (14, 15), and pediocin PA-1/AcH (a repre-
sentative of a series of class II bacteriocins that present a C-termi-
nal moiety that specifically recognizes susceptible bacteria) (16).
In this article, the results obtained from those experiments are
reported.
Lactobacillus plantarum LL441 was used for plantaricin C pro-
duction, using essentially the procedure described by González
et al. (17). Nisin A and pediocin PA-1/AcH were obtained from
Sigma. The HeLa (ATCC CCL-2) and HT-29 (ATCC HTB-38)
cell lines were used for bacteriocin activity testing and were prop-
agated according to the instructions of the supplier.
Bacteriocin activity on confluent HT-29 cell cultures was tested
by the addition of each bacteriocin at 1 g/ml (final concentra-
tion) and incubation for 24 h. No morphological changes were
observed in the cells (Fig. 1A, compare photograph a with photo-
graphs e, i, and m). Similar results were obtained when the bacte-
riocins were used at 10g/ml (data not shown). Correspondingly,
no viability losses were perceived after trypan blue staining of the
cultures (Fig. 2B, dark-gray histograms).
Incubation of HeLa cell cultures with the bacteriocins pro-
duced similar results (Fig. 1B, compare photographs a and e for
nisin A action), thus indicating that the resistance observed was
not a peculiarity of HT-29 cells. Similar results were obtained for
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plantaricin C- and pediocin PA-1/AcH-treated cultures (data not
shown).
Hydrolysis of heparan sulfate or chondroitin sulfate from
HT-29 and HeLa cells was achieved by overnight incubation at
37°C with a mix of 500 mU/ml each of heparinases I, II, and III
(Sigma) or 250 mU/ml chondroitinase ABC (Sigma), respectively
(final concentrations). Elimination of the two GAG types was
achieved by successive incubation of the cell cultures with the
enzymes, with an intermediate washing in phosphate-buffered sa-
line buffer. No morphological or viability alterations were ob-
served with respect to a control culture (Fig. 1A and B for HT-29
and HeLa cells, respectively; compare photographs a with photo-
graphs b, c, and d in each case).
The incubation of GAG-deprived HT-29 cultures with any of the
three bacteriocins resulted in evident changes in cell morphology and
abundance (Fig. 1A, photographs e to h for nisin A, i to l for plantari-
cin C, and m to p for pediocin PA-1/AcH). Similar outcomes were
obtained with the HeLa cultures (Fig. 1B, photographs e to h illustrate
the effect of nisin A on HeLa cells; similar pictures were obtained for
the other two bacteriocins). These alterations were especially notice-
able in the cultures treated with both the heparinases and chondroiti-
nase. These data indicate that GAGs effectively protect eukaryotic
cells from bacteriocin attack and that this protection is dependent on
heparan and chondroitin sulfate.
To confirm the role of the GAGs in protection against a bacte-
riocin attack, we inhibited the last step of their biosynthesis,
FIG 1 Appearance of HT-29 (A) and HeLa (B) cell cultures after exposure to bacteriocins, GAG-degrading enzymes, or both. Only enzyme treatments combined
with bacteriocins resulted in changes in the concentrations and morphologies of the cultured cells. Representative images of results obtained from at least 3
independent experiments are shown.
Martín et al.
678 aac.asm.org January 2015 Volume 59 Number 1Antimicrobial Agents and Chemotherapy
 o
n
 February 22, 2016 by O
VIEDO
 LIBRARY
http://aac.asm
.org/
D
ow
nloaded from
 
namely, heteropolysaccharide sulfation, through incubation of
the cell cultures in 25 mM sodium chlorate (Sigma)-containing
medium for 24 h (18, 19). The chlorate did not inhibit culture
growth (Fig. 2A, photographs a and b, and Fig. 2B, control). The
abolition of GAG biosynthesis resulted in cultures that were sus-
ceptible to nisin A, plantaricin C, and pediocin PA-1/AcH (Fig.
2A, photographs e, h, and k, respectively, and Fig. 2B, light gray).
Finally, we found that the simultaneous addition of any bacte-
riocin and heparin partially reversed the susceptibilities of the
chlorate-treated cultures, as determined by their appearance (Fig.
2A, photographs f, i, and l for nisin A, plantaricin C, and pediocin
PA-1/AcH, respectively) and the impermeability of the cells to
trypan blue (Fig. 2B, medium gray).
Final confirmation of the role of GAGs in cell protection was
obtained by observation of the reduced susceptibility of Lactococ-
cus lactis IL1403, a strain frequently used to titrate nisin A, to this
bacteriocin. In Fig. 3, it can be observed that the preincubation of
exponential-phase culture-derived L. lactis resting cells with 10
g/ml heparin for 30 min prior to the addition of nisin A pro-
duced an increase in their viabilities, as observed for chlorate-
treated eukaryotic cell cultures.
The ever-growing problem of antibiotic resistance is promot-
ing the search for alternative strategies for fighting infectious dis-
eases. One of the most promising are bacteriocins (20, 21). Most
FIG 2 Effect of the bacteriocins on HT-29 cell cultures treated with sodium chlorate and protection by heparin. (A) Microscopic appearances of the cultures after
the treatments indicated to the left of and above the photographs. (B) Cell viability as determined by trypan blue permeability of control cultures and replicas
incubated for 24 h with each of the three bacteriocins. Dark gray, untreated cells; light gray, chlorate-treated cultures; medium gray, cultures with chlorate and
heparin added simultaneously (*, P 0.05). The data shown are results from at least 3 independent experiments and are represented as means standard error
or are representative images.
FIG 3 Survival of Lactococcus lactis IL1403 exponential-phase cell suspensions
treated with increasing concentrations of nisin A (black) and nisin preincu-
bated with heparin for 30 min before addition to the cell suspensions (gray).
Significant differences (P  0.05) were obtained only for the cultures that
received the mix of nisin plus heparin from the concentration of 1.25 g/ml
nisin A and upward. The data shown are results from at least three indepen-
dent experiments and are represented as means standard error.
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are bactericidal and active at low concentrations; resistance gen-
eration is very scarce, and no adverse effects are associated with
their administration (11, 13). This is surprising, since one of their
targets is the plasma membrane, which is the most external struc-
ture of animal cells and, consequently, readily accessible.
The lack of toxicity of peptide bacteriocins in eukaryotic cells
may be due to (i) the inability to open pores in the cell membrane
due to the rigidity conferred by cholesterol (22), (ii) the lack of
docking molecules (6), and (iii) the presence of extracellular bar-
riers that would prevent the interaction of the bacteriocins with
the cell membrane. However, many proteins make pores in the
eukaryotic membrane, including amphipathic peptides, such as
the modulins (23), defensins, cathelicidins (24), and even plan-
taricin A, a bacteriocin produced by Lactobacillus plantarum (25).
Furthermore, several bacteriocins produce pores in prokaryotic
membranes and liposomes in the absence of docking molecules
(14, 26). Finally, the glycocalyx barrier hypothesis might be ful-
filled by proteoglycans, which form a net on most tissue surfaces
(27) that might prevent the penetration of bacteriocins toward the
underlying cell membrane. In addition, their component GAGs
are negatively charged, thus suggesting that they might bind the
positively charged amino acids typical of bacteriocins.
The work presented here indicates that none of the three bac-
teriocins used, chosen as representative of three peptide bacterio-
cin classes (21), exerted significant effects on either of two eukary-
otic cell types, selected as representative of the epithelial surfaces
(intestinal and genitourinary) that are most commonly in contact
with bacteriocins. Enzymatic elimination of heparan and/or
chondroitin sulfate or inhibition of their sulfation resulted in the
susceptibility of both eukaryotic cell types, whose growth became
restricted and showed altered morphology. This was observed for
the three bacteriocins, thus suggesting that proteoglycans medi-
ated the resistance of intact eukaryotic cell cultures to all of them
and that the sulfate component of their GAGs is responsible for
the resistance shown by untreated cultures. Furthermore, the in-
hibitory effect of nisin A was partly reversed by the addition of
heparin, which is a sulfated GAG, and this was observed with the
eukaryotic cell and L. lactis-susceptible cultures, thus suggesting a
charge complementarity interaction with the positively charged
bacteriocins.
In conclusion, the resistance of eukaryotic cells to peptide bac-
teriocins appears to be due to binding of the sulfate groups of
surface proteoglycans to positively charged bacteriocin amino ac-
ids, which prevents their interaction with the negatively charged
membrane phospholipids.
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